LungCare Med is committed to becoming the leader of lung navigation technology, focusing on the early diagnosis and treatment of lung diseases such as lung cancer. Lung cancer is the first killer of malignant tumors, but the "early detection, early diagnosis and early treatment" of lung cancer can significantly improve the 10-year survival rate of patients. LungCare Med is the only electromagnetic navigation system manufacturer with NMPA and EU CE certifications together, and its series of products solve the clinical dilemma of "three early" diagnosis and treatment strategy of "unable to enter, to find and to grasp precisely". As a platform technology in the field of lung cancer diagnosis and treatment, LungCare Med perfectly integrates a variety of minimally invasive diagnosis and treatment technologies, provides a more complete clinical solution, and innovatively proposes a three-channel treatment system, including through bronchoscope, through chest wall (Transthoracic), and through thoracoscope (thoracic surgery, VATS), serving for the respiratory department, thoracic surgery department and intervention department.
LungCare Med joined a number of clinical centers and scientific research institutes to be approved as a major Application Demonstration Project of the National Ministry of Science and Technology of early diagnosis and treatment of lung cancer based on electromagnetic navigation. LungCare Med will continue to adhere to the concept of "Born for Intervention, For Precise Navigation", and look forward to working together with the world to create a new era of lung disease diagnosis and treatment equipment.